Clinical trials evaluate circulating tumor DNA to guide therapeutic intensification and de-escalation in HPV-negative HNSCC, suggesting personalized treatment strategies.
ctDNA represents a potential biomarker for MRD detection and response monitoring in HPV-negative HNSCC. Despite encouraging pilot studies, clinical utility remains to be proven. Well powered, prospective, ctDNA-driven trials are essential to validate how ctDNA can guide therapeutic intensification, de-escalation, and personalized treatment strategies in HNSCC.
No takes yet. Share an insight, caveat, or question.
Galot et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: